These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 28967066)
1. Clinical implications for pro-GRP in small cell lung cancer. A single center experience. Cavalieri S; Morelli D; Martinetti A; Galli G; Nichetti F; de Braud F; Platania M Int J Biol Markers; 2018 Jan; 33(1):55-61. PubMed ID: 28967066 [TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer. Wang L; Wang D; Zheng G; Yang Y; Du L; Dong Z; Zhang X; Wang C Int J Biol Markers; 2016 Feb; 31(1):e80-7. PubMed ID: 26560853 [TBL] [Abstract][Full Text] [Related]
3. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. Niho S; Nishiwaki Y; Goto K; Ohmatsu H; Matsumoto T; Hojo F; Ohe Y; Kakinuma R; Kodama T Lung Cancer; 2000 Mar; 27(3):159-67. PubMed ID: 10699689 [TBL] [Abstract][Full Text] [Related]
4. The diagnostic and prognostic value of ProGRP in lung cancer. Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic potential of protein serum biomarkers for distinguishing small and non-small cell lung cancer in patients with suspicious lung lesions. Sua LF; Serrano-Gomez SJ; Nuñez M; Amezquita-Dussan MA; Fernández-Trujillo L Biomarkers; 2024 Jul; 29(5):315-323. PubMed ID: 38804910 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A Single-Center Experience in China. Wu XY; Hu YB; Li HJ; Wan B; Zhang CX; Zhang B; Hu H; Zhang Q; Lv TF; Zhan P; Song Y J Cell Mol Med; 2018 Sep; 22(9):4328-4334. PubMed ID: 29989303 [TBL] [Abstract][Full Text] [Related]
7. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318 [TBL] [Abstract][Full Text] [Related]
8. [Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency]. Shen D; Han BB; Chen F; Wei BJ; Cui CJ; Wang GJ; Cui W Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2657-2662. PubMed ID: 28910952 [No Abstract] [Full Text] [Related]
9. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients. Yang DW; Zhang Y; Hong QY; Hu J; Li C; Pan BS; Wang Q; Ding FH; Ou JX; Liu FL; Zhang D; Zhou JB; Song YL; Bai CX Cancer; 2015 Sep; 121 Suppl 17():3113-21. PubMed ID: 26331818 [TBL] [Abstract][Full Text] [Related]
10. Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer. Sunaga N; Tsuchiya S; Minato K; Watanabe S; Fueki N; Hoshino H; Makimoto T; Ishihara S; Saito R; Mori M Oncology; 1999; 57(2):143-8. PubMed ID: 10461062 [TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer. Nisman B; Heching N; Biran H; Barak V; Peretz T Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245 [TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of ProGRP31-98 in patients with small-cell lung cancer]. Yang J; Li R; Li A Zhonghua Zhong Liu Za Zhi; 2000 May; 22(3):216-8. PubMed ID: 11778234 [TBL] [Abstract][Full Text] [Related]
14. The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy. Liu X; Zhang W; Yin W; Xiao Y; Zhou C; Hu Y; Geng S Medicine (Baltimore); 2017 Nov; 96(46):e8258. PubMed ID: 29145241 [TBL] [Abstract][Full Text] [Related]
15. Prediction of lung cancer based on serum biomarkers by gene expression programming methods. Yu Z; Chen XZ; Cui LH; Si HZ; Lu HJ; Liu SH Asian Pac J Cancer Prev; 2014; 15(21):9367-73. PubMed ID: 25422226 [TBL] [Abstract][Full Text] [Related]
16. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Molina R; Augé JM; Bosch X; Escudero JM; Viñolas N; Marrades R; Ramírez J; Carcereny E; Filella X Tumour Biol; 2009; 30(3):121-9. PubMed ID: 19506400 [TBL] [Abstract][Full Text] [Related]
17. [Utility of NSE, ProGRP and LDH in Diagnosis and Treatment in Patients with Small Cell Lung Cancer]. Peng Y; Wang Y; Li J; Hao X; Hu X Zhongguo Fei Ai Za Zhi; 2016 Sep; 19(9):590-4. PubMed ID: 27666548 [TBL] [Abstract][Full Text] [Related]
18. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Shibayama T; Ueoka H; Nishii K; Kiura K; Tabata M; Miyatake K; Kitajima T; Harada M Lung Cancer; 2001 Apr; 32(1):61-9. PubMed ID: 11282430 [TBL] [Abstract][Full Text] [Related]
19. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement. Yamaguchi K; Aoyagi K; Urakami K; Fukutani T; Maki N; Yamamoto S; Otsubo K; Miyake Y; Kodama T Jpn J Cancer Res; 1995 Jul; 86(7):698-705. PubMed ID: 7559089 [TBL] [Abstract][Full Text] [Related]
20. Value of tumour and inflammatory markers in lung cancer. Oremek GM; Sauer-Eppel H; Bruzdziak TH Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]